X4 PHARMACEUTICALS, INC Proceeds from Issuance of Redeemable Convertible Preferred Stock
X4 PHARMACEUTICALS, INC (XFOR) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $40.05 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2019-03-11
- X4 PHARMACEUTICALS, INC proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2017-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2017-09-30 was $5.00M.
- X4 PHARMACEUTICALS, INC proceeds from issuance of redeemable convertible preferred stock for fiscal 2017 was $40.05M, a 628.24% increase from fiscal 2016.
- X4 PHARMACEUTICALS, INC proceeds from issuance of redeemable convertible preferred stock for fiscal 2016 was $5.50M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $5.00M derived: sum of 2 quarters · filed 2019-03-11 | $40.05M 10-K · filed 2019-03-11 | |
| 2017-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $40.05M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $35.05M 10-Q · filed 2018-08-13 | |||
| 2016-12-31 | $5.50M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |